PRPH vs. KPTI, RENB, ARTV, OTLK, VNRX, PEPG, ATNM, STTK, ICCC, and VRCA
Should you be buying ProPhase Labs stock or one of its competitors? The main competitors of ProPhase Labs include Karyopharm Therapeutics (KPTI), Renovaro (RENB), Artiva Biotherapeutics (ARTV), Outlook Therapeutics (OTLK), VolitionRx (VNRX), PepGen (PEPG), Actinium Pharmaceuticals (ATNM), Shattuck Labs (STTK), ImmuCell (ICCC), and Verrica Pharmaceuticals (VRCA). These companies are all part of the "pharmaceutical products" industry.
ProPhase Labs vs.
ProPhase Labs (NASDAQ:PRPH) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, community ranking, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.
In the previous week, Karyopharm Therapeutics had 5 more articles in the media than ProPhase Labs. MarketBeat recorded 11 mentions for Karyopharm Therapeutics and 6 mentions for ProPhase Labs. ProPhase Labs' average media sentiment score of 0.33 beat Karyopharm Therapeutics' score of 0.23 indicating that ProPhase Labs is being referred to more favorably in the media.
Karyopharm Therapeutics received 430 more outperform votes than ProPhase Labs when rated by MarketBeat users. Likewise, 72.44% of users gave Karyopharm Therapeutics an outperform vote while only 48.93% of users gave ProPhase Labs an outperform vote.
ProPhase Labs has higher earnings, but lower revenue than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.
Karyopharm Therapeutics has a consensus price target of $43.20, suggesting a potential upside of 737.21%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Karyopharm Therapeutics is more favorable than ProPhase Labs.
9.4% of ProPhase Labs shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 20.7% of ProPhase Labs shares are held by company insiders. Comparatively, 3.0% of Karyopharm Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
ProPhase Labs has a beta of -0.47, suggesting that its share price is 147% less volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500.
Karyopharm Therapeutics has a net margin of -52.62% compared to ProPhase Labs' net margin of -217.64%. Karyopharm Therapeutics' return on equity of 0.00% beat ProPhase Labs' return on equity.
Summary
Karyopharm Therapeutics beats ProPhase Labs on 11 of the 18 factors compared between the two stocks.
Get ProPhase Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProPhase Labs Competitors List
Related Companies and Tools
This page (NASDAQ:PRPH) was last updated on 5/21/2025 by MarketBeat.com Staff
Buy PRPH Stock Free PRPH Stock Alerts